<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro LiuJia1CaoRuiyuan2XuMingyue13WangXi1ZhangHuanyu13HuHengrui13LiYufeng13http://orcid.org/0000-0002-1560-0928HuZhihonghuzh@wh.iov.cn1ZhongWuzhongwu@bmi.ac.cn2WangManliwangml@wh.iov.cn1[1], 0000000119573309grid.9227.eState Key Laboratory of Virology, Wuhan"/>
 <result pre="(grant no. 2018ZX09711003 to W.Z.) Dear Editor, The outbreak of" exact="coronavirus disease" post="2019 (COVID-19) caused by the severe acute respiratory syndrome"/>
 <result pre="no. 2018ZX09711003 to W.Z.) Dear Editor, The outbreak of coronavirus" exact="disease" post="2019 (COVID-19) caused by the severe acute respiratory syndrome"/>
 <result pre="outbreak of coronavirus disease 2019 (COVID-19) caused by the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat"/>
 <result pre="of coronavirus disease 2019 (COVID-19) caused by the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to"/>
 <result pre="coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to global"/>
 <result pre="drugs, remdesivir (GS-5734) and chloroquine (CQ) phosphate, efficiently inhibited SARS-CoV-2" exact="infection" post="in vitro1. Remdesivir is a nucleoside analog prodrug developed"/>
 <result pre="of China. CQ (N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used to treat" exact="malaria" post="and amebiasis. However, Plasmodium falciparum developed widespread resistance to"/>
 <result pre="of malaria. In addition, an overdose of CQ can cause" exact="acute" post="poisoning and death3. In the past years, due to"/>
 <result pre="animals4. More importantly, HCQ is still widely available to treat" exact="autoimmune" post="diseases, such as systemic lupus erythematosus and rheumatoid arthritis."/>
 <result pre="is still widely available to treat autoimmune diseases, such as" exact="systemic" post="lupus erythematosus and rheumatoid arthritis. Since CQ and HCQ"/>
 <result pre="still widely available to treat autoimmune diseases, such as systemic" exact="lupus erythematosus" post="and rheumatoid arthritis. Since CQ and HCQ share similar"/>
 <result pre="to treat autoimmune diseases, such as systemic lupus erythematosus and" exact="rheumatoid arthritis." post="Since CQ and HCQ share similar chemical structures and"/>
 <result pre="idea that HCQ may be a potent candidate to treat" exact="infection" post="by SARS-CoV-2. Actually, as of February 23, 2020, seven"/>
 <result pre="Whether HCQ is as efficacious as CQ in treating SARS-CoV-2" exact="infection" post="still lacks the experimental evidence. To this end, we"/>
 <result pre="end, we evaluated the antiviral effect of HCQ against SARS-CoV-2" exact="infection" post="in comparison to CQ in vitro. First, the cytotoxicity"/>
 <result pre="in vitro. First, the cytotoxicity of HCQ and CQ in" exact="African" post="green monkey kidney VeroE6 cells (ATCC-1586) was measured by"/>
 <result pre="compounds against SARS-CoV-2 were determined at four different multiplicities of" exact="infection" post="(MOIs) by quantification of viral RNA copy numbers in"/>
 <result pre="at four different multiplicities of infection (MOIs) by quantification of" exact="viral" post="RNA copy numbers in the cell supernatant at 48 h"/>
 <result pre="RNA copy numbers in the cell supernatant at 48 h post" exact="infection" post="(p.i.). The data summarized in Fig. 1a and Supplementary"/>
 <result pre="concentration (EC50) for CQ (2.71, 3.81, 7.14, and 7.36 μM) was" exact="lower" post="than that of HCQ (4.51, 4.06, 17.31, and 12.96 μM)."/>
 <result pre="adaptation of the virus in cell culture that significantly increased" exact="viral" post="infectivity upon continuous passaging. Consequently, the selectivity index (SI = CC50/EC50)"/>
 <result pre="and mechanism of action of CQ and HCQ against SARS-CoV-2" exact="infection" post="in vitro. a Cytotoxicity and antiviral activities of CQ"/>
 <result pre="and is shown in b. Representative confocal microscopic images of" exact="viral" post="particles (red), EEA1+ EEs (green), or LAMP1+ ELs (green)"/>
 <result pre="ELs, which appears to be a requirement to release the" exact="viral" post="genome as in the case of SARS-CoV7. Interestingly, we"/>
 <result pre="enlarged EE vesicles were observed (Fig. 1c, arrows in the" exact="upper" post="panels), many of which are even larger than ELs"/>
 <result pre="expanded cytoplasmic vesicles8. Within the EE vesicles, virions (red) were" exact="localized" post="around the membrane (green) of the vesicle. CQ treatment"/>
 <result pre="in the number and size of ELs; however, the regular" exact="vesicle" post="structure seemed to be disrupted, at least partially. By"/>
 <result pre="number of ELs increased significantly (Fig. 1c, arrows in the" exact="lower" post="panels). Since acidification is crucial for endosome maturation and"/>
 <result pre="function, we surmise that endosome maturation might be blocked at" exact="intermediate" post="stages of endocytosis, resulting in failure of further transport"/>
 <result pre="lack of studies on the impact of HCQ on the" exact="morphology" post="and pH values of endosomes/lysosomes. Our observations suggested that"/>
 <result pre="infected with SARS-CoV-2, suggesting that cytokine storm was associated with" exact="disease" post="severity12. Other than its direct antiviral activity, HCQ is"/>
 <result pre="and successful anti-inflammatory agent that has been used extensively in" exact="autoimmune" post="diseases and can significantly decrease the production of cytokines"/>
 <result pre="conclusion, our results show that HCQ can efficiently inhibit SARS-CoV-2" exact="infection" post="in vitro. In combination with its anti-inflammatory function, we"/>
 <result pre="effects of chloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 7.MingoRMet al.Ebola virus and severe" exact="acute" post="respiratory syndrome coronavirus display late cell entry kinetics: evidence"/>
 <result pre="of chloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 7.MingoRMet al.Ebola virus and severe acute" exact="respiratory" post="syndrome coronavirus display late cell entry kinetics: evidence that"/>
 <result pre="chloroquineLancet Infect. Dis.20066676910.1016/S1473-3099(06)70361-916439323 7.MingoRMet al.Ebola virus and severe acute respiratory" exact="syndrome" post="coronavirus display late cell entry kinetics: evidence that transport"/>
 <result pre="10.PopertAJCholoroquine: a reviewRheumatology19761523523810.1093/rheumatology/15.3.235 11.LaaksonenALKoskiahdeVJuvaKDosage of antimalarial drugs for children with" exact="juvenile" post="rheumatoid arthritis and systemic lupus erythematosus. A clinical study"/>
 <result pre="a reviewRheumatology19761523523810.1093/rheumatology/15.3.235 11.LaaksonenALKoskiahdeVJuvaKDosage of antimalarial drugs for children with juvenile" exact="rheumatoid arthritis" post="and systemic lupus erythematosus. A clinical study with determination"/>
 <result pre="reviewRheumatology19761523523810.1093/rheumatology/15.3.235 11.LaaksonenALKoskiahdeVJuvaKDosage of antimalarial drugs for children with juvenile rheumatoid" exact="arthritis" post="and systemic lupus erythematosus. A clinical study with determination"/>
 <result pre="of antimalarial drugs for children with juvenile rheumatoid arthritis and" exact="systemic" post="lupus erythematosus. A clinical study with determination of serum"/>
 <result pre="antimalarial drugs for children with juvenile rheumatoid arthritis and systemic" exact="lupus erythematosus." post="A clinical study with determination of serum concentrations of"/>
</results>
